Polish Myeloma Consortium

The Polish Myeloma Consortium (PMC) is a prominent academic research organization and non-profit foundation based in Poland, dedicated to advancing the treatment of multiple myeloma through investigator-initiated clinical trials. The consortium coordinates a network of leading hematology centers to evaluate innovative therapeutic regimens, often focusing on novel combinations of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. PMC integrates clinical practice with translational research to optimize treatment protocols and improve patient outcomes across Central and Eastern Europe. The organization is a key member of the European Myeloma Network and collaborates extensively with both academic institutions and pharmaceutical partners to facilitate access to modern therapies.